As of 6 Nov 2026, Gian Life Care is loss-making on a trailing 12-month basis, with a net loss of ₹0.95 Cr, so it has no P/E ratio. The share price is ₹4.15, 69% below its 52-week high. Sales fell 25% a year over 3 years. Debt is 0.31× equity. It is a small-cap company with a market cap of ₹4.29 Cr, ranked 18th of 18 Diagnostics & Research companies by market cap; the shares fell 65% over the past year.
- ₹4.38
- ₹4.38
- ₹4.14
- ₹4.31
- 4.8K
Health check
- ReturnsBehind
−64.6% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −25.3% a year over 3 years.
- ProfitabilityWeak
ROCE 2.4% vs peer median 19.1%.
- Balance sheetStretched
Debt 0.31× equity, interest covered 1.1×, Piotroski 4 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹4.29 Cr
- Small cap
- P/E
- n/a
- Industry 52.8
- Price to book
- 0.23
- Peers 11.99
- Dividend yield
- 0.00%
- ROE
- −0.2%
- Peers 17.7%
- ROCE
- 2.4%
- Peers 19.1%
- Debt to equity
- 0.31
- Debt ₹5.73 Cr
- EPS (TTM)
- −₹0.94
- OPM (TTM)
- 3.6%
- Net margin −25.3%
- Sales growth
- −29.3%
- Latest quarter vs a year ago
- Profit growth
- −70.6%
- Latest quarter vs a year ago
- Price to sales
- 1.14
- EV/EBITDA 39.6
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −0.2%.
- Quarterly profit down 70.6% on a year ago.
- Quarterly sales down 29.3% on a year ago.
- 69% below its 52-week high.
About Gian Life Care
Gian Life Care Limited provides diagnostic and related healthcare tests and services primarily in India. It offers patient diagnosis, as well as prevention and wellness diagnosis services. The company also provides various types of tests, such as biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, etc. It serves patients, healthcare providers, hospitals, and corporate customers. The company was incorporated in 2018 and is…
- Headquarters
- Kanpur
- Employees
- 24
- Sector
- Healthcare
- ISIN
- INE063601012
- Website
- gianlifecare.org
Price range
- Avg volume (3M)
- 5.3K
- 1-year return
- minus 64.6%
- From 52-week high
- minus 68.6%
Peers · Diagnostics & Research
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAILIFESai Life Sciences | 1,785.10 | plus 11.95% | 37,929 | 101.5 | 15.22 | 18.1% | 15.1% | 28.7% | 21.3% | 226.8% | 0.00% | plus 72.7% |
| LALPATHLABDr. Lal Path Labs | 1,970.00 | plus 0.16% | 32,941 | 56.5 | 11.99 | 25.7% | 22.6% | 30.2% | 11.1% | 28.3% | 1.02% | plus 24.7% |
| SYNGENESyngene International | 417.30 | plus 0.77% | 16,772 | 90.3 | 3.46 | 8.3% | 3.9% | 25.7% | 5.4% | −12.0% | 0.30% | minus 36.0% |
| VIJAYAVijaya Diagnostic Centre | 1,468.60 | plus 2.15% | 15,126 | 74.4 | 14.29 | 19.1% | 21.2% | 43.1% | 21.0% | 26.9% | 0.14% | plus 40.2% |
| METROPOLISMetropolis Healthcare | 568.75 | minus 0.39% | 11,803 | 52.8 | 7.17 | 15.7% | 14.6% | 21.7% | 12.7% | 10.0% | 0.35% | plus 12.5% |
| THYROCAREThyrocare Technologies | 493.10 | plus 0.68% | 7,848 | 55.0 | 14.75 | 33.8% | 26.4% | 32.2% | 16.7% | 36.2% | 1.89% | plus 8.3% |
| VIMTALABSVimta Labs | 496.45 | minus 2.14% | 2,219 | 27.9 | 4.52 | 21.0% | 17.7% | 34.7% | 8.9% | 17.2% | 0.40% | minus 23.3% |
| GIANLIFEGian Life Care | 4.15 | minus 3.71% | 4 | – | 0.23 | 2.4% | −0.2% | 3.6% | −25.3% | – | 0.00% | minus 64.6% |
| Median of 7 peers | – | 0.68% | 15,126 | 56.5 | 11.99 | 19.1% | 17.7% | 30.2% | 12.7% | 26.9% | 0.35% | 12.5% |
Quarterly results
| ₹ Cr | Mar 25 | Jun 25 | Sep 25 | Dec 25 |
|---|---|---|---|---|
| 1.1 | 0.9 | 0.7 | 1.1 | |
| 0.9 | 0.7 | 1.1 | 0.9 | |
| 0.2 | 0.1 | −0.4 | 0.2 | |
| 14.7% | 15.5% | −62.0% | 22.0% | |
| −0.4 | 0.2 | 0.1 | 0.1 | |
| 0.1 | 0.1 | 0.1 | 0.1 | |
| 0.3 | 0.1 | 0.1 | 0.1 | |
| −0.6 | 0.1 | −0.5 | 0.1 | |
| 7.6% | 35.1% | 6.4% | −35.5% | |
| −0.6 | 0.1 | −0.5 | 0.1 | |
| – | 0.05 | -0.50 | 0.10 |
Profit & loss
- Sales CAGR 3Y
- −25.3%
- ROE
- −0.2%
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| 15.9 | 11.9 | 13.1 | 6.6 | |
| – | minus 25.1% | +10.0% | minus 49.5% | |
| 9.9 | 10.1 | 6.9 | 5.5 | |
| 6 | 1.8 | 6.2 | 1.1 | |
| 37.8% | 15.5% | 47.2% | 16.3% | |
| 0.5 | 0.7 | 0.6 | 0.2 | |
| 0.4 | 0.4 | 0.5 | 0.5 | |
| 0.3 | 0.5 | 0.5 | 0.6 | |
| – | – | −0 | −0.1 | |
| 5.8 | 1.6 | 5.7 | 0 | |
| 25.3% | 33.2% | 27.8% | 196.9% | |
| 4.4 | 1.1 | 4.2 | −0 | |
| – | minus 75.7% | +290.4% | minus 100.9% | |
| 4.23 | 1.03 | 4.01 | -0.04 |
Forecast
Balance sheet
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| 10.3 | 10.3 | 10.3 | 10.3 | |
| 3.7 | 4.8 | 8.9 | 8.9 | |
| 4.5 | 4.6 | 4.9 | 5.8 | |
| 4.5 | 8.6 | 8.5 | 10.9 | |
| 23.1 | 28.2 | 32.6 | 35.9 | |
| 3.6 | 8.1 | 8.8 | 7.8 | |
| 0.1 | 3.5 | 3.8 | 3.4 | |
| 0.3 | 0.3 | 0.3 | – | |
| 4.9 | 5.8 | 6 | 7 | |
| 14.2 | 10.5 | 13.7 | 17.8 | |
| 23.1 | 28.2 | 32.6 | 35.9 |
Cash flow
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| 1.3 | 2.2 | 0.7 | 0.3 | |
| −0.5 | −0.9 | −0.3 | 0.3 | |
| 1.5 | −0.4 | −0.2 | 0.5 | |
| 2.3 | 0.9 | 0.2 | 1 | |
| −1 | −1.6 | −1 | −0 | |
| 0.4 | 0.6 | −0.3 | 0.3 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.